Amneal Pharmaceuticals Income Statement (2017-2026) | AMRX

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	535.08M	528.59M	536.90M	497.63M	559.36M	545.56M	-1582.74M	557.54M	599.05M	620.04M	616.98M	659.19M	701.78M	702.47M	730.52M	695.42M	724.51M	784.51M	814.32M	722.52M
Cost of Revenue (Quarter)	1.36M	1.63M	1,318.12M	0.76M	0.82M	1.41M	394.37M	379.35M	379.02M	387.51M	427.15M	421.13M	451.83M	432.91M	467.64M	439.53M	438.25M	510.54M	517.13M	402.41M
Gross Profit (Quarter)	212.50M	198.51M	166.40M	174.57M	200.52M	194.23M	215.39M	178.19M	220.02M	232.53M	189.83M	238.06M	249.95M	269.56M	262.87M	255.89M	286.25M	273.97M	297.19M	320.11M
Operating items
Research & Development (Quarter)	52.86M	48.93M	51.87M	52.80M	50.75M	50.23M	41.91M	38.69M	37.80M	41.38M	46.09M	39.30M	36.05M	61.10M	54.27M	40.04M	47.96M	63.35M	34.82M	38.38M
Selling, General & Administrative (Quarter)	86.16M	91.40M	97.22M	98.67M	98.81M	100.07M	102.16M	102.10M	105.57M	113.01M	109.00M	112.59M	116.46M	118.69M	128.69M	118.29M	124.27M	137.81M	146.46M	138.86M
Restructuring Costs (Quarter)		0.42M	7.31M	0.73M		0.58M	-0.61M	0.51M	0.08M	1.04M	0.11M	1.47M	0.22M	0.17M	0.49M	0.57M	1.02M	0.14M	2.47M	5.15M
Other Operating Expenses (Quarter)		-19.00M	18.80M	2.30M	1.90M	1.32M	249.10M	0.44M	-0.01M	-0.07M	-2.94M	-94.40M	-0.70M	0.15M	95.83M			0.12M		-0.69M
Operating Expenses (Quarter)	139.02M	140.75M	156.41M	152.19M	149.55M	150.89M	143.45M	141.30M	143.45M	155.42M	155.20M	153.36M	152.74M	179.96M	183.44M	158.90M	173.25M	201.31M	183.75M	182.40M
Operating Income (Quarter)	67.12M	28.52M	11.18M	0.10M	-198.62M	44.35M	138.06M	34.45M	80.08M	75.65M	14.19M	-10.75M	95.47M	88.81M	75.79M	100.35M	111.37M	70.34M	112.03M	141.77M
EBIT (Quarter)	67.12M	28.52M	11.18M	0.10M	-198.62M	44.35M	138.06M	34.45M	80.08M	75.65M	14.19M	-10.75M	95.47M	88.81M	75.79M	100.35M	111.37M	70.34M	112.03M	141.77M
Non-operating items
Other Non Operating Income (Quarter)		-0.03M	-8.70M	-2.01M	6.94M	-5.49M	-15.06M	4.37M	0.42M	-2.94M	1.63M	4.07M	4.36M			4.25M	1.60M	1.24M	-0.04M	-3.51M
Non Operating Income (Quarter)	-32.30M	-30.56M	-27.49M	-33.23M	-34.11M	-42.17M	-41.85M	-49.31M	-50.42M	-52.69M	-93.56M	-64.78M	-75.06M	-73.39M	-91.11M	-62.86M	-59.66M	-75.57M	-56.80M	-61.60M
Net income details
EBT (Quarter)	34.82M	-2.04M	-16.32M	-9.92M	-232.73M	2.18M	-7.66M	-9.43M	29.66M	22.96M	-83.46M	-75.52M	20.41M	15.42M	-15.32M	37.49M	51.71M	-5.22M	55.23M	80.18M
Tax Provisions (Quarter)	2.61M	4.00M	4.14M	-3.46M	7.35M	4.57M	-1.84M	0.70M		-2.08M	9.88M	6.16M	3.62M	3.67M	5.42M	12.87M	16.10M	-23.36M	5.66M	2.18M
Profit After Tax (Quarter)	32.18M	-6.09M	-20.46M	-8.82M	-240.08M	-7.61M	3.77M	-6.94M	29.68M	9.68M	-98.65M	-91.64M	5.99M	11.76M	-63.75M	12.20M	22.42M	2.37M	49.57M	62.26M
Income from Non-Controlling Interests (Quarter)	17.64M	-1.85M	-14.08M	-4.74M	-119.27M	0.30M	-1.52M	-3.15M	17.77M	15.35M	5.30M	9.96M	10.79M	11.91M	10.34M	12.42M	13.19M	15.76M	14.50M	15.74M
Income from Continuing Operations (Quarter)	32.22M	-6.04M	-20.46M	-6.46M	-240.08M	-2.39M	-5.82M	-10.13M	29.66M	25.03M	-93.34M	-81.68M	16.79M	11.76M	-20.74M	24.62M	35.61M	18.13M	49.57M	78.00M
Consolidated Net Income (Quarter)	32.22M	-6.04M	-20.46M	-6.46M	-240.08M	-2.39M	-5.82M	-10.13M	29.66M	25.03M	-93.34M	-81.68M	16.79M	11.76M	-20.74M	24.62M	35.61M	18.13M	49.57M	78.00M
Income towards Parent Company (Quarter)	14.53M	-4.24M	-6.38M	-1.72M	-120.81M	-2.69M	-4.33M	-6.94M	11.92M	9.68M	-98.65M	-81.68M	16.79M	11.76M	-20.74M	24.62M	35.61M	18.13M	49.57M	78.00M
Preferred Dividend Payments (Quarter)				0.44M
Net Income towards Common Stockholders (Quarter)	14.53M	-4.24M	-6.38M	-2.16M	-120.81M	-2.69M	-4.33M	-6.94M	11.92M	9.68M	-98.65M	-81.68M	16.79M	11.76M	-20.74M	24.62M	35.61M	18.13M	49.57M	78.00M
Additional items
EPS (Basic) (Quarter)	0.10	-0.03	-0.04	-0.01	-0.80	-0.02	-0.03	-0.05	0.08	0.06	-0.56	-0.27	0.05	0.04	-0.07	0.08	0.11	0.06	0.16	0.25
EPS (Diluted) (Quarter)	0.10	-0.03	-0.04	-0.01	-0.80	-0.02	-0.03	-0.05	0.08	0.06	-0.56	-0.27	0.05	0.04	-0.07	0.08	0.11	0.06	0.15	0.24
Shares Outstanding (Quarter)	149.00M	149.29M	148.92M	149.89M	150.99M	151.39M	150.94M	152.11M	153.74M	154.22M	176.14M	307.28M	309.12M	309.65M	308.98M	311.05M	313.74M	314.17M	313.37M	316.02M
Shares Outstanding (Diluted) (Quarter)	151.99M	149.29M	151.82M	149.89M	150.99M	151.39M	150.94M	152.11M	154.89M	159.69M	176.14M	307.28M	318.96M	309.65M	308.98M	323.96M	322.36M	324.75M	324.81M	328.93M
EBITDA (Quarter)	67.12M	28.52M	11.18M	0.10M	-198.62M	44.35M	138.06M	34.45M	80.08M	75.65M	14.19M	-10.75M	95.47M	88.81M	75.79M	100.35M	111.37M	70.34M	112.03M	141.77M
Interest Expenses (Quarter)	174.59M	100.18M	-82.78M	64.16M	72.13M	71.89M	50.51M	435.40M	435.40M	434.50M	56.21M	566.00M	565.70M	66.37M	-193.71M	92.39M	85.88M	126.30M	41.40M	117.74M
Tax Rate (Quarter)	7.49%	-195.79%	-25.37%	34.89%	-3.16%	209.63%	24.01%	-7.43%		-9.04%	-11.84%	-8.15%	17.73%	23.77%	-35.40%	34.33%	31.14%	447.16%	10.25%	2.71%

Research Tools

Developers

Amneal Pharmaceuticals Income Statement (2017-2026) | AMRX

Research Tools

Developers

Amneal Pharmaceuticals Income Statement (2017-2026) | AMRX

Create an account

Sign In

Reset Password